Product Images Levetiracetam

The figure shows the Responder Rate with a 250% reduction from the baseline in Study 1. There is a statistically significant difference compared to the placebo. The rest of the text contains some percentages and medication names with unclear context.*

This is a description of Levetiracetam tablets USP, a medication used for seizures. Each film-coated tablet contains Levetiracetam USP 1000mg, and the usual dosage should be taken as per the package insert. It is recommended to store the tablets in a tight, light-resistant container with a child-resistant closure at a temperature between 20-25°C. The tablets are distributed by Rising Pharma Holdings, Inc. and were made in India. The text also includes a code and a printing/coding area.*

This is a graphic representation of the responder rate in a study conducted with three different groups of patients: those receiving a placebo, those taking 1000 mg/day of the medication Levetiracetam, and those taking 2000 mg/day of the same medication. The percentages represent the proportion of patients in each group who experienced a 250% reduction from their baseline symptoms. One of the groups taking 2000 mg/day showed a statistically significant improvement compared to the placebo group.*

This is a figure from a medical study (Study 3) showing the responder rate of patients who experienced a reduction of more than 50% from their baseline in the symptoms being treated. The responder rate was 45% for the placebo group (N=104) and 39.4% for the group receiving 3000mg per day of Levetiracetam (N=180). The figure also indicates that the Levetiracetam group had a statistically significant improvement compared to the placebo group.*

The text describes a figure named "Figure 4" that displays the responder rate in a study referred to as "Study 4". The graph shows that the responder rate was 44.6% and 45% for the Levetiracetam (N=101) group, respectively. For the placebo group (N=97), the responder rate was 19.6%. The figure suggests that the Levetiracetam group had a statistically significant higher responder rate compared to the placebo group.*

Figure 5 shows the Responder Rate for patients between 1 month and less than 4 years, with more than 50% reduction from the initial results, as recorded in Study 5. The percentage of Responder Rate is not available as the readings are inaccurate. However, Lovetracatam proved statistically significant compared to placebo in this study.*

This figure displays the responder rate in PGTC seizure frequency per week in Study 7. The graph shows the percentage of patients who had a 250% reduction from baseline in seizure frequency. The percentages for placebo and Levetiracetam (a medication) are shown on the y-axis, ranging from 0% to 100%. The x-axis shows the number of patients. The graph indicates that 72.2% of patients taking Levetiracetam had a 250% reduction in seizure frequency, compared to only 45.2% of patients taking placebo. The difference is statistically significant.*

Levetiracetam is a medication manufactured by Rising Pharma Holdings, Inc. Each film-coated tablet contains 500mg of Levetiracetam USP. Complete dosage recommendations can be found in the package insert. The drug should be dispensed in a tight, light-resistant container with a child-resistant closure. It should be stored at 20°C to 25°C (68°F to 77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F). A medication guide is provided separately. Printed lines in the overprinting zone coding area are not to be printed.*